Batista Rita, Nunes Baltazar, Carmo Manuela, Cardoso Carlos, José Helena São, de Almeida António Bugalho, Manique Alda, Bento Leonor, Ricardo Cândido Pinto, Oliveira Maria Margarida
Instituto Nacional de Saúde Dr Ricardo Jorge, Lisboa, Portugal.
J Allergy Clin Immunol. 2005 Aug;116(2):403-10. doi: 10.1016/j.jaci.2005.04.014.
The safety issues regarding foods derived from genetically modified (GM) plants are central to their acceptance into the food supply. The potential allergenicity of proteins newly introduced in GM foods is a major safety concern.
We sought to monitor, in potentially sensitive human populations, the allergenicity effects of 5 GM materials obtained from sources with no allergenic potential and already under commercialization in the European Union.
We have performed skin prick tests with protein extracts prepared from transgenic maize (MON810, Bt11, T25, Bt176) and soya (Roundup Ready) samples and from nontransgenic control samples in 2 sensitive groups: children with food and inhalant allergy and individuals with asthma-rhinitis. We have also tested IgE immunoblot reactivity of sera from patients with food allergy to soya (Roundup Ready) and maize (MON810, Bt11, Bt176) samples, as well as to the pure transgenic proteins (CryIA[b] and CP4 5-enolpyruvylshikimate-3-phosphate synthase).
None of the individuals undergoing tests reacted differentially to the transgenic and nontransgenic samples under study. None of the volunteers tested presented detectable IgE antibodies against pure transgenic proteins.
The transgenic products under testing seem to be safe in terms of allergenic potential. We propose postmarket testing as an important screening strategy for putative allergic sensitization to proteins introduced in transgenic plants.
转基因植物源性食品的安全性问题是其能否进入食品供应领域的核心。转基因食品中新引入蛋白质的潜在致敏性是一个主要的安全问题。
我们试图在潜在敏感人群中监测5种转基因材料的致敏性影响,这些材料来自无致敏潜力且已在欧盟商业化的来源。
我们用从转基因玉米(MON810、Bt11、T25、Bt176)和大豆(抗草甘膦)样本以及非转基因对照样本制备的蛋白质提取物,对两个敏感组进行了皮肤点刺试验:食物和吸入性过敏儿童以及哮喘-鼻炎患者。我们还检测了对大豆(抗草甘膦)和玉米(MON810、Bt11、Bt176)样本以及纯转基因蛋白(CryIA[b]和CP4 5-烯醇丙酮酸莽草酸-3-磷酸合酶)过敏的患者血清的IgE免疫印迹反应性。
接受测试的个体对所研究的转基因和非转基因样本均无差异反应。接受测试的志愿者中没有一人呈现出针对纯转基因蛋白的可检测到的IgE抗体。
就致敏潜力而言,所测试的转基因产品似乎是安全的。我们建议将上市后检测作为对转基因植物中引入的蛋白质进行假定过敏致敏的重要筛查策略。